A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy
PHASE2CompletedINTERVENTIONAL
Enrollment
36
Participants
Timeline
Start Date
Not specified
Study Completion Date
June 30, 2004
Conditions
HIV Infections
Interventions
DRUG
Aldesleukin
Trial Locations (1)
Unknown
Kobler Ctr. of Chelsea Westminster Hosp. C604-030 CRS, London
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)